Plasma metabolomics of oral squamous cell carcinomas based on NMR and MS approaches provides biomarker identification and survival prediction

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
POLACHINI, Giovana Mussi
CASTRO, Tialfi Bergamin de
SMARRA, Luis Fabiano Soares
HENRIQUE, Tiago
PAULA, Carlos Henrique Diniz de
SEVERINO, Patricia
CARVALHO, Andre Lopes
ZERI, Ana Carolina de Mattos
SILVA, Ismael Dale Cotrim Guerreiro
Citação
SCIENTIFIC REPORTS, v.13, n.1, article ID 8588, 21p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Metabolomics has proven to be an important omics approach to understand the molecular pathways underlying the tumour phenotype and to identify new clinically useful markers. The literature on cancer has illustrated the potential of this approach as a diagnostic and prognostic tool. The present study aimed to analyse the plasma metabolic profile of patients with oral squamous cell carcinoma (OSCC) and controls and to compare patients with metastatic and primary tumours at different stages and subsites using nuclear magnetic resonance and mass spectrometry. To our knowledge, this is the only report that compared patients at different stages and subsites and replicates collected in diverse institutions at different times using these methodologies. Our results showed a plasma metabolic OSCC profile suggestive of abnormal ketogenesis, lipogenesis and energy metabolism, which is already present in early phases but is more evident in advanced stages of the disease. Reduced levels of several metabolites were also associated with an unfavorable prognosis. The observed metabolomic alterations may contribute to inflammation, immune response inhibition and tumour growth, and may be explained by four nonexclusive views-differential synthesis, uptake, release, and degradation of metabolites. The interpretation that assimilates these views is the cross talk between neoplastic and normal cells in the tumour microenvironment or in more distant anatomical sites, connected by biofluids, signalling molecules and vesicles. Additional population samples to evaluate the details of these molecular processes may lead to the discovery of new biomarkers and novel strategies for OSCC prevention and treatment.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59128
Referências
  1. Aliu E, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.12.12
  2. Anderson JC, 2021, OBES SCI PRACT, V7, P646, DOI 10.1002/osp4.516
  3. Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238-017-0451-1
  4. Bag S, 2015, BIOCHEM BIOPH RES CO, V459, P574, DOI 10.1016/j.bbrc.2015.02.149
  5. Barrilero R, 2017, J PROTEOME RES, V16, P1847, DOI 10.1021/acs.jproteome.6b00814
  6. Beckham TH, 2010, EXPERT OPIN THER TAR, V14, P529, DOI 10.1517/14728221003752768
  7. Bian YJ, 2020, NATURE, V585, P277, DOI 10.1038/s41586-020-2682-1
  8. Boguszewicz L, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1576-4
  9. Boguszewicz L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126310
  10. Bonomi M, 2014, ADV EXP MED BIOL, V816, P107, DOI 10.1007/978-3-0348-0837-8_5
  11. Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
  12. Bota AB, 2021, ALCOHOL CLIN EXP RES, V45, P666, DOI 10.1111/acer.14568
  13. Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004
  14. Calvani R, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010199
  15. Cartwright MM, 2012, CRIT CARE CLIN, V28, P601, DOI 10.1016/j.ccc.2012.07.001
  16. Cernei N, 2013, INT J MOL SCI, V14, P13893, DOI 10.3390/ijms140713893
  17. Chen YP, 2019, ANN ONCOL, V30, P68, DOI 10.1093/annonc/mdy470
  18. Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6
  19. da Silva IDCG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75862-4
  20. Czystowska-Kuzmicz M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10979-3
  21. Dauvilliers Y, 2022, NEUROLOGY, V98, pE493, DOI 10.1212/WNL.0000000000013128
  22. de Toro-Martín J, 2018, J CLIN LIPIDOL, V12, P311, DOI 10.1016/j.jacl.2017.10.020
  23. DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683
  24. Dorgan JF, 2020, CANCER CAUSE CONTROL, V31, P113, DOI 10.1007/s10552-019-01256-1
  25. Duskova K, 2018, IN VIVO, V32, P425, DOI 10.21873/invivo.11257
  26. El-Sayed S, 2002, HEAD NECK-J SCI SPEC, V24, P766, DOI 10.1002/hed.10125
  27. Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
  28. Emwas AH, 2019, METABOLITES, V9, DOI 10.3390/metabo9070123
  29. Erlic Z, 2019, EUR J ENDOCRINOL, V181, P647, DOI 10.1530/EJE-19-0589
  30. Felder TK, 2017, J SCI MED SPORT, V20, P700, DOI 10.1016/j.jsams.2016.11.011
  31. Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
  32. Friedman R, 2018, J MEMBRANE BIOL, V251, P609, DOI 10.1007/s00232-018-0050-y
  33. Fukao T, 2014, J INHERIT METAB DIS, V37, P541, DOI 10.1007/s10545-014-9704-9
  34. Furuya H, 2011, CANCER METAST REV, V30, P567, DOI 10.1007/s10555-011-9304-1
  35. Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031
  36. Goetzman Eric S, 2017, Curr Genet Med Rep, V5, P132, DOI 10.1007/s40142-017-0125-6
  37. Gupta A, 2015, CLIN CHIM ACTA, V441, P47, DOI 10.1016/j.cca.2014.12.003
  38. Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
  39. Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
  40. Haukaas TH, 2017, METABOLITES, V7, DOI 10.3390/metabo7020018
  41. Hoover RN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju398
  42. Hou CX, 2022, ANN SURG ONCOL, V29, P7386, DOI 10.1245/s10434-022-12098-8
  43. Hoy AJ, 2021, NAT REV CANCER, V21, P753, DOI 10.1038/s41568-021-00388-4
  44. Isaac R, 2021, CELL METAB, V33, P1744, DOI 10.1016/j.cmet.2021.08.006
  45. Kaiser P, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040568
  46. Kamarajan P, 2017, J PROTEOME RES, V16, P1315, DOI 10.1021/acs.jproteome.6b00936
  47. Kanikarla-Marie P, 2015, CELL PHYSIOL BIOCHEM, V35, P364, DOI 10.1159/000369702
  48. Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003
  49. Keshet R, 2018, NAT REV CANCER, V18, P634, DOI 10.1038/s41568-018-0054-z
  50. Kim MJ, 2015, INT J CLIN EXP PATHO, V8, P7967
  51. Knific T, 2018, J STEROID BIOCHEM, V178, P312, DOI 10.1016/j.jsbmb.2018.01.012
  52. Kompare M, 2008, SEMIN PEDIATR NEUROL, V15, P140, DOI 10.1016/j.spen.2008.05.008
  53. Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007
  54. Kumar D, 2016, PROSTATE, V76, P1106, DOI 10.1002/pros.23198
  55. Langenau J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102331
  56. Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11
  57. Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
  58. León X, 2021, ORAL ONCOL, V115, DOI 10.1016/j.oraloncology.2021.105184
  59. Li C, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.955614
  60. Lionaki E, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11020214
  61. Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722
  62. Lohavanichbutr P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204249
  63. Long B, 2021, J EMERG MED, V61, P658, DOI 10.1016/j.jemermed.2021.09.007
  64. Longo N, 2016, BBA-MOL CELL RES, V1863, P2422, DOI 10.1016/j.bbamcr.2016.01.023
  65. Ma EH, 2017, CELL METAB, V25, P345, DOI 10.1016/j.cmet.2016.12.011
  66. Mahajan VR, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.781668
  67. Markin PA, 2020, LAB MED, V51, P566, DOI 10.1093/labmed/lmaa008
  68. Marquês JT, 2018, PROG LIPID RES, V71, P18, DOI 10.1016/j.plipres.2018.05.001
  69. Meiser J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03777-w
  70. Mikalayeva V, 2021, BIOCHEM BIOPH RES CO, V585, P61, DOI 10.1016/j.bbrc.2021.11.034
  71. Munir R, 2019, BRIT J CANCER, V120, P1090, DOI 10.1038/s41416-019-0451-4
  72. Najumudeen AK, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00753-3
  73. Newman JC, 2017, ANNU REV NUTR, V37, P51, DOI 10.1146/annurev-nutr-071816-064916
  74. Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
  75. Papalazarou V, 2021, MOL CELL, V81, P3731, DOI 10.1016/j.molcel.2021.08.026
  76. Pavlova NN, 2022, CELL METAB, V34, P355, DOI 10.1016/j.cmet.2022.01.007
  77. Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
  78. Piirtola M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200140
  79. Podbielska M, 2016, J LIPID RES, V57, P2028, DOI 10.1194/jlr.M070664
  80. Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770
  81. Poff AM, 2014, INT J CANCER, V135, P1711, DOI 10.1002/ijc.28809
  82. Polesel J, 2017, ORAL ONCOL, V67, P175, DOI 10.1016/j.oraloncology.2017.02.009
  83. Pongnopparat T, 2021, AMINO ACIDS, V53, P1589, DOI 10.1007/s00726-021-03078-5
  84. Porporato PE, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.3
  85. Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
  86. Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022
  87. Quell JD, 2019, METABOLITES, V9, DOI 10.3390/metabo9060109
  88. Ragin CC, 2011, HEAD NECK-J SCI SPEC, V33, P1092, DOI 10.1002/hed.21584
  89. Ridgway ND, 2013, CRIT REV BIOCHEM MOL, V48, P20, DOI 10.3109/10409238.2012.735643
  90. Rodríguez-Tomàs E, 2020, J PROTEOMICS, V213, DOI 10.1016/j.jprot.2019.103605
  91. Ron-Harel N, 2019, CELL REP, V28, P3011, DOI 10.1016/j.celrep.2019.08.034
  92. Rutkowsky JM, 2014, AM J PHYSIOL-ENDOC M, V306, pE1378, DOI 10.1152/ajpendo.00656.2013
  93. Saito RD, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.768606
  94. Sanderson SM, 2019, NAT REV CANCER, V19, P625, DOI 10.1038/s41568-019-0187-8
  95. Schönfeld P, 2016, J LIPID RES, V57, P943, DOI 10.1194/jlr.R067629
  96. Schulz D, 2018, EUR ARCH OTO-RHINO-L, V275, P1239, DOI 10.1007/s00405-018-4920-9
  97. Sessa L, 2021, MEMBRANES-BASEL, V11, DOI 10.3390/membranes11100787
  98. Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
  99. Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166
  100. Shrivastava S, 2018, ADV EXP MED BIOL, V1112, P141, DOI 10.1007/978-981-13-3065-0_10
  101. Shulaev V, 2018, J CHROMATOGR B, V1092, P499, DOI 10.1016/j.jchromb.2018.06.021
  102. Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311
  103. Singh A, 2020, NAT METHODS, V17, P24, DOI 10.1038/s41592-019-0710-6
  104. [Sobin L.H. UICC UICC], 2002, TNM CLASSIFICATION M, V6th
  105. Soeters PB, 2012, ANN NUTR METAB, V60, P17, DOI 10.1159/000334880
  106. Somashekar BS, 2011, J PROTEOME RES, V10, P5232, DOI 10.1021/pr200800w
  107. Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305
  108. Strand E, 2019, METABOLITES, V9, DOI 10.3390/metabo9120302
  109. Strmiska V, 2019, MOL ONCOL, V13, P1002, DOI 10.1002/1878-0261.12439
  110. Sugimoto M, 2010, METABOLOMICS, V6, P78, DOI 10.1007/s11306-009-0178-y
  111. Suzuki S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38299
  112. Svingen GFT, 2016, CLIN CHEM, V62, P755, DOI 10.1373/clinchem.2015.250761
  113. Tajan M, 2018, CELL METAB, V28, P721, DOI 10.1016/j.cmet.2018.07.005
  114. Takagi A, 2022, J CACHEXIA SARCOPENI, V13, P287, DOI 10.1002/jcsm.12906
  115. Takeuchi Y, 2018, BIOCHEM BIOPH RES CO, V495, P761, DOI 10.1016/j.bbrc.2017.11.088
  116. Tiziani S, 2009, NEOPLASIA, V11, P269, DOI 10.1593/neo.81396
  117. Torres A, 2016, J LEUKOCYTE BIOL, V99, P387, DOI 10.1189/jlb.4A0615-252R
  118. Tripathi P, 2012, INT J BIOCHEM CELL B, V44, P1852, DOI 10.1016/j.biocel.2012.06.025
  119. Vitório JG, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01727-6
  120. Walters RO, 2018, CELL REP, V25, P663, DOI 10.1016/j.celrep.2018.09.065
  121. Wang M, 2018, MED SCI MONITOR, V24, P3034, DOI 10.12659/MSM.909949
  122. Wang YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87489
  123. Wang ZF, 2021, MOLECULES, V26, DOI 10.3390/molecules26206308
  124. Wei JE, 2011, INT J CANCER, V129, P2207, DOI 10.1002/ijc.25881
  125. Wei Z, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.603837
  126. White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113
  127. Wu DJ, 2017, SEMIN CELL DEV BIOL, V64, P125, DOI 10.1016/j.semcdb.2016.11.003
  128. Xia JG, 2011, NAT PROTOC, V6, P743, DOI 10.1038/nprot.2011.319
  129. Xie GX, 2012, METABOLOMICS, V8, P220, DOI 10.1007/s11306-011-0302-7
  130. Xie SB, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/5558458
  131. Xu H, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108401
  132. Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81
  133. Zhou JL, 2009, CLIN CHIM ACTA, V401, P8, DOI 10.1016/j.cca.2008.10.030
  134. Zhou Y, 2013, CLIN BIOCHEM, V46, P1447, DOI 10.1016/j.clinbiochem.2013.05.045

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP